How to Cite
Abstract
Ovarian cancer is one of the most aggressive malignant tumors in women. The role of hormone therapy in the treatment for ovarian cancer is not fully studied up to now. The literature contains data on the efficacy and safety of treatment with antiestrogens and aromatase inhibitors for recurrent ovarian cancer. The article summarizes the epidemiology, preclinical and clinical studies related to the role of estrogen and aromatase expression in this disease as well as the role of aromatase inhibitors in the treatment for ovarian cancer.References
Бохман Я.В. Руководство по онкогинекологии. Медицина. - 1989. - с.464.
Abu-Jawdeh G.M., Jacobs T.W., Niloff J., Cannistra S.A. Estrogen receptor expression is a common feature of ovarian borderline tumors // Gynecol Oncol. - 1996. Vol. 60. - P. 301-307.
Berstein L., Tehernobrovkina A., Gamajunova V. et al. Tumor estrogen content and clinic-morphological and endocrine features of endometrial cancer // J. Cancer Res Clin Oncol. - 2003. - Vol. 129(4). - P. 245-249.
Berstein L., Maximov S., Gershfeld E. et al. Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects // Eur J Obstet Gynecol Reprod Biol. - 2002. - Vol. 105. - P. 161-165.
Bowman A., Gabra H., Langdon S.P. et al. CA125 response is associated with estrogen receptor expression in a phase II trial of letrozole in ovarian cancer: identification of an endocrine-sensitive subgroup // Clin Cancer Res. - 2002. - Vol. 8. - P. 2233-2239.
Brandenberger A.W., Tee M.K., Lee J.Y., Chao V., Jaffe R.B. Tissue distribution of estrogen receptors alpha (ER-alpha) and beta (ER-beta) mRNA in the midgestational human fetus // J Clin Endocrinol Metab. - 1997. - Vol. 82. - P. 3509-3512.
Bulun S., Lin Z., Imir G. et al. Regulation of aromatase expression in estrogen-responsive breast and uterine disease: from bench to treatment // Pharmacol Rev. - 2005. - Vol. 57(3). - P. 359-383.
Bulun S., Simpson E. Aromatase Expression in Women’s Cancers. Innovative Endocrinology of Cancer, ed. by L. Berstein and R. Santen, ch.8; 2008, pp. 112-132.
Chien C.H., Wang F.F., Hamilton T.C. Transcriptional activation of cmyc proto-oncogene by estrogen in human ovarian cancer cells // Mol Cell Endocrinol. - 1994. - Vol. 99. - P. 11-19.
Choi K.C., Kang S.K., Tai C.J., Auersperg N., Leung P.C. Estradiol upregulates antiapoptotic Bcl-2 messenger ribonucleic acid and protein in tumorigenic ovarian surface epithelium cells // Endocrinology. - 2001. - Vol. 142. - P. 2351-2360.
Clinton G.M., Rougeot C., Derancourt J. et al. Estrogens increase the expression of fibulin-1, an extracellular matrix protein secreted by human ovarian cancer cells // Proc Natl Acad Sci U S A. - 1996. - Vol. 93. P. 316-320.
Cunat S., Rabenoelina F., Daures J.P. et al. Aromatase expression in ovarian epithelial cancers // J Steroid Biochem Mol Biol. - 2005. - Vol. 93. - P. 15-24.
del Carmen M.G., Fuller A.F., Matulonis U. et al. Phase II trial of anastrozole in women with asymptomatic mullerian cancer // Gynecol Oncol. - 2003. - Vol. 91. - P. 596-602.
Galtier-Dereure F., Capony F., Maudelonde T., Rochefort H. Estradiol stimulates cell growth and secretion of procathepsin D and a 120-kilodalton protein in the human ovarian cancer cell line BG-1 // J Clin Endocrinol Metab. - 1992. - Vol. 75. - P. 1497-502.
Grodin J., Siiteri P., MacDonald P. Source of estrogen production in postmenopausal women // J Clin Endocrinol Metab. - 1973. - Vol. 36. - P. 207-214.
Guo R.X., Wei L.H., Tu Z. et al. 17 beta-estradiol activates PI3K/Akt signaling pathway by estrogen receptor (ER)-dependent and ERindependent mechanisms in endometrial cancer cells // J Steroid Biochem Mol Biol. - 2006. - Vol. 99. - P. 9-18.
Herzog T.J. Recurrent ovarian cancer: how important is it to treat to disease progression? // Clin Cancer Res. - 2004. - Vol. 10. - P. 7439-7449.
Hillier S.G., Anderson R.A., Williams A.R., Tetsuka M. Expression of oestrogen receptor alpha and beta in cultured human ovarian surface epithelial cells // Mol Hum Reprod. - 1998. - Vol. 4. - P. 811-815.
Howell A., Cuzick J., Baum M. et al. Results of the ATAC (Arimidex, Tamoxifen, alone or in combination) trial after completion of 5 years’ adjuvant treatment for breast cancer // Lancet. - 2005. - Vol. 365. - P. 60-62.
Hua W., Christianson T., Rougeot C., Rochefort H., Clinton G.M. SKOV3 ovarian carcinoma cells have functional estrogen receptor but are growth-resistant to estrogen and antiestrogens // J Steroid Biochem Mol Biol. - 1995. - Vol. 55. - P. 279-289.
Johnston S.R. Combinations of endocrine and biological agents: present status of therapeutic and presurgical investigations // Clin Cancer Res. - 2005. - Vol. 11. - P. 889s-899.
Kamat A., Mendelson C.R. Identification of the regulatory regions of the human aromatase P450 (CYP19) gene involved in placentaspecific expression // J Steroid Biochem Mol Biol. - 2001. - Vol. 79. - P. 173-180.
Kavanagh J.J., Hu W., Fu S.Q. et al. Anti-tumor activity of letrozole in patients with recurrent advanced low malignant potential or low grade serous ovarian tumors // J Clin Oncol (2007 ASCO Annual Meeting Proceedings, Chicago, IL). - 2007 Vol. 25. - No. 185 (Abstract 5582).
Kimura A., Ohmichi M., Kawagoe J. et al. Induction of hTERT expression and phosphorylation by estrogen via Akt cascade in human ovarian cancer cell lines // Oncogene. - 2004. - Vol. 23. - P. 4505-4515.
Krasner C.N., Debernardo R.L., Findley M. et al. Phase II trial of anastrazole in combination with gefitinib in women with asymptomatic mullerian cancer // Proc Am Soc Clin Oncol. - 2005. - Abstract # 5063.
Labrie F. Intracrinology // Mol Cell Endocrinol. - 1991. - Vol. 78. - P. 113-118.
Li Y.F., Hu W. Aromatase inhibitors in ovarian cancer: is there a role? // Int J Gynecol Cancer. - 2008. Vol. 18. - P. 600-614.
Mabuchi S., Ohmichi M., Kimura A. et al. Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin // Endocrinology. - 2004. - Vol. 145. - P. 1302-1313.
Miller W.R. Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. // Semin Oncol. - 2003. - Vol. 30. - P. 3-11.
Munstedt K., Steen J., Knauf A.G. et al. Steroid hormone receptors and long term survival in invasive ovarian cancer // Cancer. - 2000. - Vol. 89. - P. 1783-1791.
O’Donnell A.J., Macleod K.G., Burns D.J., Smyth J.F., Langdon S.P. Estrogen receptor-alpha mediates gene expression changes and growth response in ovarian cancer cells exposed to estrogen // Endocr Relat Cancer. - 2005 - Vol. 12. - P. 851-866.
Osborne C.K., Schiff R. Estrogen-receptor biology: continuing progress and therapeutic implications // J Clin Oncol. - 2005. - Vol. 23. - P. 1616-1622.
Osborne C.K., Shou J., Massarweh S., Schiff R. Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer // Clin Cancer Res. - 2005. - Vol. 11. - P. 865s-870s.
Papadimitriou C., Markaki S., Siapkaras J. et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study // Oncology. - 2004. - Vol. 66(2). - P. 112-117.
Papadimitriou C.A., Markaki S., Siapkaras J. et al. Hormonal therapy with letrozole for relapsed epithelial ovarian cancer. Long-term results of a phase II study // Oncology. - 2004. - Vol. 66. - P. 112-117.
Parkin D., F. Bray F., J. Ferley et al. Global cancer statistics, 2002. - CA Cancer J Clin. - 2005. - Vol. 55. - P. 74-108.
Riman T., Dickman P.W., Nilsson S. et al. Hormone replacement therapy and the risk of invasive epithelial ovarian cancer in Swedish women // J Natl Cancer Inst. - 2002. - Vol. 94. - P. 497-504.
Russo J., Hasan Lareef M., Balogh G., Guo S., Russo I.H. Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells // J Steroid Biochem Mol Biol. - 2003. - Vol. 87. - P. 1-25.
Sasano H., Sato S., Ito K. et al. Effect of aromatase inhibitors on thepathobiology of human breast, endometrial and ovarian carcinoma // Endocrinol. Related.Cancer. - 1999. - Vol. 6(2). - P. 197-204.
Simpson E., Clyne C., Rubin G. et al. Aromatase - a brief overview // Annu Rev Physiol. - 2002. - Vol. 64. - P. 93-127.
Simpson E.R., Zhao X., Agarwal V.R. et al. Aromatase expression in health and disease // Recent Prog Horm Res. - 1997. - Vol. 52. - P. 185-213;
Somigliana E., Vigano P., Parazzini F. et al. Association between endometriosis and cancer: a comprehensive review and a critical analysis of clinical and epidemiological evidence // Gynecol Oncol. - 2006. - Vol. 101(2). - P. 331-341.
Song J., Fadiel A., Edusa V. et al. Estradiol-induced ezrin overexpression in ovarian cancer: a new signaling domain for estrogen // Cancer Lett. - 2005. - Vol. 220. - P. 57-65.
Trope C., Marth C., Kaern J. Tamoxifen in the treatment of recurrent ovarian carcinoma // Eur J Cancer. - 2000. - Vol. 36(Suppl. 4). - S59-61.
Tsai E.M., Wang S.C., Lee J.N., Hung M.C. Akt activation by estrogen in estrogen receptor-negative breast cancer cells // Cancer Res. - 2001. - Vol. 61. - P. 8390-8392.
Urmancheeva A.F., Meshkova I.E. Question of epidemiology and diagnostics of ovarian cancer // Prac Oncol. - 2000. - Vol. 4. - P. 7-13.
Verma S., Alhayki M., Le T. et al. Phase II study of exemestane (E) in refractory ovarian cancer (ROC) // J Clin Oncol (2006 ASCO Annual Meeting, Atlanta, GA). - 2006. - Vol. 24. - Abstract #5026.
All the Copyright statements for authors are present in the standart Publishing Agreement (Public Offer) to Publish an Article in an Academic Periodical 'Problems in oncology' ...